Skip to main content

Table 4 Global applicability of MASK

From: MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

Applicability MASK
Clinical practice Physicians will be able to read the files of the patients in order to
   Optimize treatment for the patient and, in particular, the current or the next pollen season
   Assess and increase the adherence to treatment
   Help for shared decision making
   Prescribe allergen immunotherapy (AIT) more rapidly when the patient is not controlled despite optimal pharmacologic treatment
   Determine the efficacy of AIT in patients
   The Allergy Diary is an essential tool to provide personalized medicine in AR and asthma
Change management The first results of MASK indicate that many patients are uncontrolled and non-adherent to treatment
  Moreover, they appear to use their medications as needed and not as a regular basis as prescribed
  Change management is needed
Patient empowerment Better understanding of the symptoms
  Sentinel network linking aerobiology data and control
  Improved adherence
  Self-management
  Patient empowerment
  Messages sent by the App
Clinical trials For RCTs, it is essential to have clarity on definitions, and relevant tools. The Allergy Diary allows
   To better stratify the patients needing AIT
   To assess the efficacy of AIT during the trial
   To assess the efficacy when AIT is stopped
  Observational studies are of key importance to confirm RCTs and bring new hypotheses for the treatment of AR and asthma
Registration and reimbursement of medicines Controlled trials designed with a uniform approach will be more easily evaluated by the Health Technology Assessment agencies (such as NICE) for reimbursement. The Allergy Diary uses EQ-5D, a validated measure of utility
  Better understanding of direct and indirect costs
  Controlled trials designed with a uniform approach will help to synchronize data from real-life world regarding clinical effects and safety/tolerability of new drugs (post-marketing pharmacovigilance
Research on mechanisms and genetics A uniform definition and a collaborative approach to epidemiological, genetic and mechanistic research are important and will be enhanced by the stratification of patients using the Allergy Diary
  Different levels of phenotype characterization (granularity) can be applied to assess phenotypic characterization in old age subjects
Epidemiology In epidemiologic population studies, standardized definitions and tools are fundamental. The Allergy Diary allows novel approaches combining classical cross-sectional and longitudinal studies with real life studies in large populations
Employers AR and asthma represent a major burden for the employers, and the estimated annual costs in the EU range from 30 to 60 B€. Better control of the disease was shown to reduce costs. The Allergy Diary has the potential to improve the control of allergic diseases and to significantly improve work productivity at the EU level
Public health planning For public health purposes, a perfect patient characterization in real life is needed to identify the prevalence, burden and costs incurred by patients in order to improve quality of care and optimize health care planning and policies
Reduction of inequities Inequities still exist in the EU for allergic diseases prevalence and burden (not only sex/gender inequities). POLLAR will attempt to understand them and to propose policies and health promotion strategies